Salivary CD5L as a Potential Non-Invasive Biomarker for Pathological Staging and Prognostic Assessment in Oral Squamous Cell Carcinoma
Diagnostics · 16.06.2026 · 16 (12) · 1856
DOI: 10.3390/diagnostics16121856 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.06.2026. Verfasst von Nan-Chin Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Show Chwan Memorial Hospital, Changhua 500, Taiwan. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSTC.
Abstract (Originalsprache)
Background/Objectives: In Taiwan, more than 50% of patients with oral cancer seek medical help at a late stage. Reliable non-invasive biomarkers for pathological staging and disease monitoring are still lacking. This study aimed to identify a specific biomarker associated with late-stage oral cancer and to develop a non-invasive strategy for early pathological diagnosis and disease monitoring with improved patient acceptability.
Methods
A total of 116 participants were enrolled, including 31 patients with early-stage oral cancer, 49 with late-stage oral cancer, and 36 healthy controls. Saliva samples were collected for proteomic analysis, and the findings were validated using ELISA and tissue immunohistochemistry. The identified biomarker was validated, and its tumor-promoting role was confirmed using malignant phenotype assays, including colony formation, soft agar, migration, and invasion assays.
Results
Our results demonstrate that CD5L expression could not be distinguished between early- and late-stage groups using tissue immunohistochemistry. In contrast, salivary CD5L levels differentiated early-stage from late-stage patients noninvasively. Functional studies demonstrated that CD5L suppression markedly attenuated malignant phenotypes (colony formation, anchorage-independent growth, migration, invasion), suggesting its involvement in tumor aggressiveness and metastatic potential.
Conclusions
These findings provide new insights into the pathological role of salivary CD5L in oral cancer progression and support its potential as a non-invasive biomarker for disease stratification.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Show Chwan Memorial Hospital, Changhua 500, Taiwan.
- Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807378, Taiwan.
- Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong 10340, Indonesia.
- School of Dentistry, China Medical University, Taichung 404328, Taiwan.
- Department of Healthcare Administration, Asia University, Taichung 413305, Taiwan.
ORCID-Profile: Nan-Chin Lin, Yu-Hsin Tseng, Tzong-Ming Shieh, Yin-Hwa Shih
Förderung
- NSTC
Zitieren
APA
Lin, N. C., Tseng, Y. H., Panjaitan, N. S. D., Tsai, K. Y., Huang, K. M., Lan, W. C., Shieh, T. M., & Shih, Y. H. (2026). Salivary CD5L as a Potential Non-Invasive Biomarker for Pathological Staging and Prognostic Assessment in Oral Squamous Cell Carcinoma. Diagnostics, 16(12), 1856. https://doi.org/10.3390/diagnostics16121856
Vancouver
Lin NC, Tseng YH, Panjaitan NSD, Tsai KY, Huang KM, Lan WC, et al. Salivary CD5L as a Potential Non-Invasive Biomarker for Pathological Staging and Prognostic Assessment in Oral Squamous Cell Carcinoma. Diagnostics. 2026;16(12):1856. doi:10.3390/diagnostics16121856
BibTeX
@article{Lin2026,
author = {Lin, Nan-Chin and Tseng, Yu-Hsin and Panjaitan, Novaria Sari Dewi and Tsai, Kuo-Yang and Huang, Kuan-Min and Lan, Wan-Chen and Shieh, Tzong-Ming and Shih, Yin-Hwa},
title = {Salivary CD5L as a Potential Non-Invasive Biomarker for Pathological Staging and Prognostic Assessment in Oral Squamous Cell Carcinoma},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {12},
pages = {1856},
doi = {10.3390/diagnostics16121856}
}
EUVIMED